Cantrell Drug Recalls Glycopyrrolate Injection Syringes Due to Sterility Concerns
Cantrell Drug Company is recalling specific lots of Glycopyrrolate Injection Solution due to a lack of sterility assurance. The affected syringes were distributed nationwide.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a lack of sterility assurance in an injectable medication, which poses a significant risk of serious injury or infection.
Plain-English summary
Cantrell Drug Company is voluntarily recalling specific lots of Glycopyrrolate Injection Solution, 1 mL 0.2 mg/1 mL (0.2 mg/mL) Single-Dose Syringes. The recall was initiated because of a lack of sterility assurance for the affected product.
The recalled product includes NDC 52533-028-45. The specific lots affected are 9868 (Best Use Date: 8/9/2017), 9872 (Best Use Date: 8/10/2017), and 10318 (Best Use Date: 10/7/2017). A total of 5,245 syringes were distributed nationwide within the United States.
Healthcare providers and patients should check their inventory and medication records for these specific lot numbers and expiration dates. If the product matches the recalled lots, it should be discontinued and returned to the supplier or disposed of according to local regulations. Patients should consult their healthcare provider for alternative treatment options if necessary.
The recalled product
- Product
- Glycopyrrolate Injection Solution, 1 mL 0.2 mg/1 mL (0.2 mg/mL) Single-Dose Syringe, Rx Only, Cantrell Drug Company 7321 Cantrell Rd Little Rock, AR 72207 877-666-5222; NDC 52533-028-45
- Manufacturer
- Cantrell Drug Company
- Category
- Drug — Injectable Medication
- Hazard
- Affected units
- 5,245
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot #: 9868
- BUD: 8/9/2017
- 9872
- BUD: 8/10/2017
- 10318
- BUD: 10/7/2017
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 18 recalled by Cantrell Drug Company under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 18 products in this recall →Related recalls
Same manufacturer · Cantrell Drug Company
See all →- SevereCantrell Drug Company Recalls Rocuronium Bromide Injection Due to Sterility Concerns
FDA (Drugs) · 2017-08-16
- SevereCantrell Drug Recalls Succinylcholine Chloride Injection Due to Sterility Concerns
FDA (Drugs) · 2017-08-16
- SevereCantrell Drug Recalls Norepinephrine Bags Due to Sterility Concerns
FDA (Drugs) · 2017-08-16
- SevereCantrell Recalls Neostigmine Methylsulfate Injection Due to Sterility Concerns
FDA (Drugs) · 2017-08-16
- SevereCantrell Drug Recalls Ephedrine Sulfate Syringes Due to Sterility Concerns
FDA (Drugs) · 2017-08-16
Same hazard · lack of sterility
See all →- HighRohto Cooling Eye Drops Max Strength Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15